SUPPLEMENTAL Table 1. Clinicopathologic characteristics of robot-assisted nipple sparing mastectomy (n = 82)

|  |  |
| --- | --- |
| Variables | number (%)a |
| Median age, years (range) | 45.5 (20–66) |
| Median BMI, kg/m2 (range) | 21.4 (16.9–30.7) |
| Menopausal status, n (%) |  |
|  Premenopause | 52 (62.5) |
|  Postmenopause | 28 (34.1) |
|  Unknown  | 2 (2.4) |
| Smoking history, n (%) |  |
|  Never smoker | 77 (93.9) |
|  Current smoker | 3 (3.6) |
|  Ex-smoker | 2 (2.4) |
| Past medical history, n (%) |  |
|  No | 77 (93.9) |
|  Yes† | 5 (6.1) |
| Prior breast surgery, n (%) |  |
|  No | 81 (98.8) |
|  Yes‡ | 1 (1.2) |
| Family history of breast cancer, n (%) |  |
|  No | 73 (89.0) |
|  Yes | 9 (11.0) |
| *BRCA1/2* mutation status, n (%) |  |
|  BRCA1 mutation | 1 (1.2) |
|  BRCA2 mutation | 6 (7.3) |
|  No examination or no mutation | 75 (91.5) |
| Preoperative diagnosis, n (%) |  |
|  DCIS | 33 (40.2) |
|  Invasive carcinoma | 40 (48.8) |
|  Risk reducing mastectomy | 9 (11.0) |
|  Benign | 6 (7.3) |
|   *BRCA1/2* mutation carrier | 3 (3.7) |
| Postoperative diagnosis, n (%) |  |
|  DCIS | 20 (24.4) |
|  Invasive carcinoma | 55 (63.4) |
|  Risk-reducing mastectomy | 7 (8.5) |
|  Benign | 4 (4.9) |
|   *BRCA1/2* mutation carrier | 3 (3.6) |
| Surgical extent, n (%) |  |
|  Unilateral | 60 (73.2) |
|  Bilateral | 22 (26.8) |
| ER, n (%) |  |
|  Negative | 11 (13.4) |
|  Positive | 63 (76.8) |
|  No examination or unknown | 7 (8.5) |
| PR, n (%) |  |
|  Negative | 20 (24.4) |
|  Positive | 54 (65.8) |
|  No examination or unknown | 7 (8.5) |
| HER2, n (%) |  |
|  No amplification | 46 (56.2) |
|  Amplification | 22 (26.8) |
|  Equivocal | 7 (8.5) |
|  No examination or unknown | 7 (8.5) |
| Ki-67, n (%) |  |
| > 14.0% | 41 (50.0) |
| ≤ 14.0% | 34 (41.5) |
|  No examination or unknown | 7 (8.5) |
| Median pathologic invasive size, mm (range) | 11.0 (0.4–66.0) |
| Median pathologic in situ or intraductal focus size, mm (range) | 25.0 (0–90.0) |
| Multiplicity, n (%) |  |
|  Single lesion | 38 (46.3) |
|  Multifocal lesions | 28 (34.1) |
|  Multicentric lesions | 9 (11.0) |
|  No examination or unknown | 7 (8.5) |
| Number of lymph node metastasis, n (%) |  |
| 0 | 66 (80.5) |
| 1–4 | 5 (6.1) |
| 4–9 | 3 (3.6) |
| ≥ 10 | 1 (1.2) |
|  No examination or unknown | 7 (8.5) |
| Grade, n (%) |  |
|  Well | 12 (14.6) |
|  Moderate | 49 (59.7) |
|  Poor or undifferentiated | 13 (15.8) |
|  No examination or unknown | 8 (9.7) |
| Sur/basal margin, n (%) |  |
|  No | 81 (98.8) |
|  Yes | 1 (1.2) |
| Nipple frozen margin, n (%) |  |
|  Negative | 74 (90.3) |
|  Positive | 1 (1.2) |
|  No examination or unknown | 7 (8.5) |
| Nipple permanent margin, n (%) |  |
|  Negative | 74 (90.3) |
|  Positive | 1 (1.2) |
|  No examination or unknown | 7 (8.5) |
| Adjuvant chemotherapy, n (%) |  |
|  No | 65 (79.3) |
|  Yes | 17 (20.7) |
| Adjuvant radiotherapy, n (%) |  |
|  No | 73 (89.0) |
|  Yes | 9 (11.0) |
| Adjuvant hormone therapy, n (%) |  |
|  No | 22 (26.8) |
|  Yes | 60 (73.2) |
| Adjuvant target therapy, n (%) |  |
|  No | 76 (92.7) |
|  Yes | 6 (7.3) |

\*Seventy-three patients underwent 82 RANSM procedures

†Three patients had hypertension and diabetes; two patients had asthma and COPD

‡One patient underwent breast-conserving surgery with axillary lymph node dissection in 2003